Innogenetics to Take €7.5M Charge in Third Quarter | GenomeWeb
NEW YORK (GenomeWeb News) – Belgian molecular diagnostics firm Innogenetics said today that it will take a non-recurring charge of €7.5 million ($10.2 million) related to impairment losses on intangible assets, fixed assets, and inventories.
Innogenetics said that the losses are tied to activities “for which the business plan at this moment does not foresee significant future revenue streams.” The firm did not provide details of which activities are related to the charges.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.